Retatrutide API Supplier Qualification: A 7-Step Review Beyond the CoA

Is a CoA enough to qualify a Retatrutide API supplier?

No. A Certificate of Analysis is an important batch record, but it is only one part of a controlled qualification. A useful review asks whether the named material, seller, actual manufacturer, physical site, batch, test laboratory, methods and specification all describe the same project scope.

The evidence depth should match the intended use and project stage. A feasibility exercise, analytical reference activity, process-development program and regulated supply chain do not require identical approvals, but each needs a documented owner, unresolved-field list and decision gate.

1. Confirm the investigational and market-status boundary

Lilly describes Retatrutide as investigational and in Phase 3 development, not approved by the U.S. FDA or available for public use. FDA separately states that Retatrutide cannot be used in compounding under U.S. federal law. Before any supply review, the requesting organization should document the legal product category, intended use, project stage, destination market and responsible regulatory owner; quality documentation cannot make an impermissible intended use acceptable.

2. Follow a seven-step supplier-qualification sequence

Use the same order for every initial review so missing evidence is visible early and teams do not mistake document volume for qualification quality.

• Define the legal category, intended use, project stage and destination market.
• Specify the exact supplied material: identity reference, modification state, counter-ion or salt where applicable, composition considerations, specification, packaging and storage.
• Identify the contracting entity, actual manufacturer, manufacturing site, testing site and each party's responsibility.
• Reconcile the label, CoA, batch identifier, manufacture and test dates, method references and available underlying records.
• Map each analytical question to its purpose: identity, purity, related impurities, content or potency, stability and other project-specific attributes.
• Review route- and process-specific impurity risks, change control, deviations, OOS responsibility and technical-transfer readiness.
• Assign quality, regulatory, IP/FTO, procurement and technical owners, then record the next review trigger.

3. Reconcile the seller, actual manufacturer, site and batch

The company issuing a quotation may be the manufacturer, an authorized contracting entity, a distributor, a broker, a repacker or another participant in the chain. These roles should not be treated as interchangeable. ICH Q7 states that manufacturers of APIs or intermediates should evaluate suppliers of critical materials, purchase against an agreed specification from quality-unit-approved suppliers, and know the name and address of the actual physical manufacturer when the supplier is not the manufacturer.

The quotation, quality questionnaire, label, CoA, batch identifier, testing-laboratory record, packaging record and shipping documents should tell one consistent story. An unexplained change in entity, site, batch number, date, testing laboratory or seller should pause the review until the discrepancy is resolved.

4. Test the analytical purpose, not only the HPLC headline

A chromatographic purity result reports what one procedure detected, separated and integrated under defined conditions. It does not by itself establish chemical identity, absolute content, modification state or every impurity risk. ICH Q2(R2) asks whether a procedure is fit for its intended purpose, while ICH Q14 connects that purpose to development knowledge, robustness and lifecycle control.

• Identity: can the evidence distinguish the intended material from plausible related materials?
• Purity: what does the chromatographic procedure separate and detect under its stated conditions?
• Impurities: which route-, process- or storage-related variants are plausible, resolved, assigned or still unknown?
• Content or potency: does the reported value answer the same question as chromatographic area percent?
• Method suitability: is the procedure appropriate for the project stage, laboratory, transfer state and change-control needs?

5–7. Separate quality, legal-market and commercial decisions

A material can produce an analytically acceptable result and still be unsuitable for the intended use, destination or legal pathway. Conversely, an investigational status does not answer whether a sample was correctly identified or whether its batch evidence is reliable. These are distinct questions with different owners and evidence.

Finish the review by recording three separate approvals: quality and technical acceptability; regulatory, IP/FTO and destination-market eligibility; and commercial responsibility for the defined supply chain. Qualification is complete only when the requesting organization has documented the decisions that apply to its project.